| 11.61 1.61 (16.1%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.35 | 1-year : | 19.42 |
| Resists | First : | 14 | Second : | 16.62 |
| Pivot price | 11.32  |
|||
| Supports | First : | 9.76 | Second : | 8.12 |
| MAs | MA(5) : | 10.76 |
MA(20) : | 11.77 |
| MA(100) : | 17.61 |
MA(250) : | 0 | |
| MACD | MACD : | -1.3 |
Signal : | -1.5 |
| %K %D | K(14,3) : | 26.8 |
D(3) : | 22.5 |
| RSI | RSI(14): 43 |
|||
| 52-week | High : | 28.22 | Low : | 9.76 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ KLRA ] has closed below upper band by 41.4%. Bollinger Bands are 28.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.82 - 11.89 | 11.89 - 11.96 |
| Low: | 9.83 - 9.91 | 9.91 - 9.98 |
| Close: | 11.48 - 11.61 | 11.61 - 11.72 |
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Fri, 09 Oct 2026
Kailera Therapeutics Inc. (KLRA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Fri, 09 Oct 2026
Kailera Therapeutics (NASDAQ:KLRA) Shares Climb 7.6% - Time to Buy? - MarketBeat
Fri, 09 Oct 2026
Kailera Therapeutics, Inc. (NASDAQ:KLRA) Stock Has Average Target Price of $42.75 - MarketBeat
Fri, 09 Oct 2026
KLRA Options Overview History for Kailera Therapeutics Stock - Barchart.com
Tue, 06 Oct 2026
Kailera Therapeutics, Inc. (KLRA) Stock Price, News, Quote & History - Yahoo! Finance Canada
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 130 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 8.9 (%) |
| Held by Institutions | 90.4 (%) |
| Shares Short | 8,680 (K) |
| Shares Short P.Month | 5,660 (K) |
| EPS | -4.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.63 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -222 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -2.58 |
| PEG Ratio | 0 |
| Price to Book value | 1.34 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|